Identification
- Summary
Inosine pranobex is a medication used to treat subacute sclerosing panencephalitis.
- Brand Names
- Imunovir
- Generic Name
- Inosine pranobex
- DrugBank Accession Number
- DB13156
- Background
Inosine pranobex (Isoprinosine or Methisoprinol) is a combination of inosine, acetamidobenzoic acid, and dimethylaminoisopropanol used as an antiviral drug.
- Type
- Small Molecule
- Groups
- Approved
- Structure
Structure for Inosine pranobex (DB13156)
- Weight
- Average: 1115.249
Monoisotopic: 1114.554641092 - Chemical Formula
- C52H78N10O17
- Synonyms
- IAD
- Inosine acedobene dimepranol
- Inosine pranobex
- Inosine-2-hydroxypropyldimethylammonium 4-acetamidobenzoate (1:3)
- Inosiplex
- Isoprinosine
- Methisoprinol
- External IDs
- NP-113
- NPT-10381
Pharmacology
- Indication
Inosine pranobex is also indicated for mucocutaneous infections due to herpes simplex virus (type 1 and type II) and for treatment of genital warts as adjunctive therapy to podophyllin or carbon dioxide laser.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Management of Subacute sclerosing panencephaliti •••••••••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Works by slowing the growth and spread of the virus in the body. It may also stimulate the immune system in the body, which helps to increase the body's ability to fight these infections.
- Mechanism of action
Inosine pranobex stimulates cell-mediated immune processes to viral infections.
- Absorption
Rapidly absorbed from GIT
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Via urine
- Half-life
50 min
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Mouse LD50 (Intravenous ): 1570 mg/kg Mouse LD50 (Oral) : 9410mg/kg Mouse LD50 (subcutaneous) ; 2960mg/kg
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbacavir Abacavir may decrease the excretion rate of Inosine pranobex which could result in a higher serum level. Aceclofenac Aceclofenac may decrease the excretion rate of Inosine pranobex which could result in a higher serum level. Acemetacin Acemetacin may decrease the excretion rate of Inosine pranobex which could result in a higher serum level. Acetaminophen Acetaminophen may decrease the excretion rate of Inosine pranobex which could result in a higher serum level. Acetazolamide Acetazolamide may increase the excretion rate of Inosine pranobex which could result in a lower serum level and potentially a reduction in efficacy. - Food Interactions
- No interactions found.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Imunovir Tablet 500 mg Oral Kora Healthcare 2000-01-25 Not applicable Canada 
Isoprinosine Tablet 500 mg Oral Newport Pharmaceuticals International 1997-06-05 2000-02-04 Canada Isoprinosine Tab 500mg Tablet 500 mg / tab Oral Systemed Inc. 1993-12-31 1996-09-10 Canada Isoprinosine Tab 500mg Tablet 500 mg Oral Newport Pharms International Inc. 1983-12-31 1996-09-10 Canada
Categories
- ATC Codes
- J05AX05 — Inosine pranobex
- Drug Categories
- Acetanilides
- Adjuvants, Immunologic
- Amides
- Amines
- Anilides
- Aniline Compounds
- Anti-Infective Agents
- Antiinfectives for Systemic Use
- Antiviral Agents
- Drugs that are Mainly Renally Excreted
- Heterocyclic Compounds, Fused-Ring
- Immunologic Factors
- Nucleic Acids, Nucleotides, and Nucleosides
- Nucleosides
- Purine Nucleosides
- Purines
- Ribonucleosides
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as purine nucleosides. These are compounds comprising a purine base attached to a ribosyl or deoxyribosyl moiety.
- Kingdom
- Organic compounds
- Super Class
- Nucleosides, nucleotides, and analogues
- Class
- Purine nucleosides
- Sub Class
- Not Available
- Direct Parent
- Purine nucleosides
- Alternative Parents
- Glycosylamines / 6-oxopurines / Pentoses / Hypoxanthines / Benzoic acids / Benzoyl derivatives / Pyrimidones / N-substituted imidazoles / Vinylogous amides / Tetrahydrofurans show 14 more
- Substituents
- 1,2-aminoalcohol / 6-oxopurine / Alcohol / Amine / Aromatic heteropolycyclic compound / Azacycle / Azole / Benzenoid / Benzoic acid / Benzoic acid or derivatives show 38 more
- Molecular Framework
- Not Available
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- W1SO0V223F
- CAS number
- 36703-88-5
- InChI Key
- YLDCUKJMEKGGFI-KSIULYHRSA-N
- InChI
- InChI=1S/C10H12N4O5.3C9H9NO3.3C5H13NO/c15-1-4-6(16)7(17)10(19-4)14-3-13-5-8(14)11-2-12-9(5)18;3*1-6(11)10-8-4-2-7(3-5-8)9(12)13;3*1-5(7)4-6(2)3/h2-4,6-7,10,15-17H,1H2,(H,11,12,18);3*2-5H,1H3,(H,10,11)(H,12,13);3*5,7H,4H2,1-3H3/t4-,6-,7-,10-;;;;3*5-/m1...111/s1
- IUPAC Name
- tris((2R)-1-(dimethylamino)propan-2-ol); tris(4-acetamidobenzoic acid); 9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6,9-dihydro-1H-purin-6-one
- SMILES
- C[C@@H](O)CN(C)C.C[C@@H](O)CN(C)C.C[C@@H](O)CN(C)C.CC(=O)NC1=CC=C(C=C1)C(O)=O.CC(=O)NC1=CC=C(C=C1)C(O)=O.CC(=O)NC1=CC=C(C=C1)C(O)=O.OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1C=NC2=C1N=CNC2=O
References
- General References
- External Links
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Unknown Status Treatment Human Immunodeficiency Virus (HIV) Infections 1 3 Unknown Status Prevention Coronavirus Disease 2019 (COVID‑19) 1 3 Unknown Status Treatment Coronavirus Disease 2019 (COVID‑19) / Respiratory Tract Infections (RTI) 1 1 Completed Treatment Human Immunodeficiency Virus (HIV) Infections 1 Not Available Completed Treatment Human Immunodeficiency Virus (HIV) Infections 3
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Syrup Oral 5.0000 g Tablet Oral 500.000 mg Syrup Oral 250 mg/5ml Tablet Oral 500 mg / tab Tablet Oral Syrup Oral Syrup Oral 5 g Capsule Cream Topical 10 % Cream Topical 20 % Granule Oral 1 g Granule, for solution Oral 1 g/5g Injection Intramuscular; Intravenous 1 g/5ml Injection Intramuscular; Intravenous 500 mg/5ml Insert Vaginal 1500 mg Syrup Oral 5 % Tablet Oral 750 MG Tablet Oral 500 mg - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 13.8 mg/mL ALOGPS logP -1.9 ALOGPS logP -2.5 Chemaxon logS -1.3 ALOGPS pKa (Strongest Acidic) 8.93 Chemaxon pKa (Strongest Basic) 0.58 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 7 Chemaxon Hydrogen Donor Count 4 Chemaxon Polar Surface Area 129.2 Å2 Chemaxon Rotatable Bond Count 14 Chemaxon Refractivity 61.33 m3·mol-1 Chemaxon Polarizability 24.6 Å3 Chemaxon Number of Rings 6 Chemaxon Bioavailability 0 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 307.53275 predictedDeepCCS 1.0 (2019) [M+H]+ 309.1981 predictedDeepCCS 1.0 (2019) [M+Na]+ 315.35492 predictedDeepCCS 1.0 (2019)
Drug created at December 04, 2016 00:28 / Updated at April 24, 2024 14:30